Cubit Diagnostics announced the closing of its latest SAFE (Simple Agreement for Future Equity) financing round as the company advances development of its integrated molecular and immunoassay diagnostic platform.
The company said the new funding will support the next phase of development work, including reaching design freeze for its CT/NG/TV molecular assay and expanding its immunoassay testing menu.
Cubit Diagnostics expects to achieve design freeze for its CT/NG/TV molecular assay during the fourth quarter of 2026, positioning the company to begin a clinical study during the first half of 2027.
The company also said it continues to make progress across its immunoassay initiatives and broader platform development efforts.
According to Cubit Diagnostics, the financing follows recent additions to its board of directors aimed at strengthening expertise across diagnostics, regulatory affairs, and commercialization.
Based in Carlsbad, California, Cubit Diagnostics is developing a benchtop diagnostic platform designed to integrate molecular testing and immunoassay capabilities into a single system intended to simplify clinical workflows and expand access to point-of-care diagnostics.
The company noted that its platform remains under development and is not currently available for diagnostic use.
KEY QUOTES:
“We have the right team, a clear path forward, and the capital to achieve the next key milestones.”
“Getting to design freeze on CT/NG/TV this year and into a clinical study in 2027 is what this phase is about.”
“We’re also making real progress on the immunoassay side, which will give us the runway to expand the menu quickly.”
Kunal Sur, CEO, Cubit Diagnostics
“Putting molecular and immunoassay into one platform is novel and compelling, and we’re incredibly excited about the progress we continue to make.”
“Locking the CT/NG/TV design and getting into a clinical study next year is a key priority.”
Kunal Sur, CEO, Cubit Diagnostics
